Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats

Objective: To determine the potential combination benefit receptor of treat ment with PEGylated soluble tumor necrosis factor type I (PEG sTNF-RI) and dexamethasone (dex) or indomethacin (indo) in adjuvant arthritic rats. Subj ects: 160 male Lewis Rats. Treatment: PEG sTNF-RI, dex, indo. Methods: Rats with adjuvant arthritis were given daily oral dex (0.025 or 0 .006 mg/kg) or indo (0.5 or 0.25 mg/kg) day 9-14, alone or in combination w ith PEG sTNF-RI (sc on days 9, 11, and 13 of arthritis). Efficacy was monit ored by volume measurement of ankle joints, final paw weights and histologi c evaluation with particular emphasis on bone lesions. Results: Treatment with 1 mg/kg PEG sTNF-RI alone resulted in 27% inhibitio n of final paw weights, dex alone (0.025 mg/kg) gave 25% inhibition and the combination resulted in 58% inhibition. Histologic evaluation of ankle joi nts demonstrated 48% inhibition of bone resorption with PEG sTNF-RI alone, 55% inhibition with dex alone and the combination treatment inhibited bone resorption by 100%. Inactive doses of PEG sTNF-RI (0.3 mg/kg) and dex (0.00 6 mg/kg) when combined resulted in 39% inhibition of paw swelling (AUC) and 39% inhibition of bone resorption. Combination treatment with indomethacin resulted in slight additive effects on inflammation parameters but no addi tive effects on bone resorption. Conclusion: Combination therapy with PEG sTNF-RI and dexamethasone results in additive or synergistic effects depending on the dose. Combination thera py with indomethacin resulted in slight additive effects on paw swelling pa rameters, but no additive benefit on bone resorption. Data from these studi es support the clinical investigation of the use of combination therapy of PEG sTNF-RI and dex or other corticosteroids in rheumatoid arthritis patien ts.